Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease
Journal
Journal of the Formosan Medical Association
Journal Volume
118
Pages
S55-S61
Date Issued
2019
Author(s)
Yang Y.-J.
Abstract
Huge amount microorganisms resides in human intestine, and many contribute to the maturation and homeostasis of immune system. The diversity of gut ecology are affected by the gestational age, delivery type, feeding sources, and antibiotics use in neonates. Recent studies pointed out that disturbance of gut microbiota, so called dysbiosis, could result in several pediatric diseases including obesity, non-alcoholic fatty liver disease (NAFLD), metabolic syndromes, allergic diseases, and inflammatory bowel diseases. However, there are no single species can be proven to play a key factor in pediatric obesity and NAFLD at present. Various probiotics may confer benefit to these gut microbiota-related pediatric diseases. The clinical application is still limited. This review article aimed to elucidate evidently the relationship between gut microbiota and pediatric obesity/NAFLD and to discuss the potential probiotics use in pediatric obesity and NAFLD. ? 2018 Formosan Medical Association
Subjects
Immunity; Microbiota; Non-alcoholic fatty liver disease; Obesity; Probiotics
SDGs
Other Subjects
probiotic agent; probiotic agent; Bifidobacterium; childhood obesity; clinical trial; drug use; feces microflora; homeostasis; human; intestine; intestine flora; Lactobacillus casei; Lactobacillus salivarius; nonalcoholic fatty liver; nonhuman; Review; child; childhood obesity; dysbiosis; host pathogen interaction; microbiology; nonalcoholic fatty liver; randomized controlled trial (topic); Child; Dysbiosis; Gastrointestinal Microbiome; Host-Pathogen Interactions; Humans; Non-alcoholic Fatty Liver Disease; Pediatric Obesity; Probiotics; Randomized Controlled Trials as Topic
Publisher
Elsevier B.V.
Type
review